Posted on by Newsdesk

PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences

P
HAXIAM
Therapeutics
publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences

Lyon (France) and Cambridge (MA, US)
,
September
5
,
2023
–
10:05 p.m. CEST –
P
HAXIAM
Therapeutics (Nasdaq & Euronext:
PHXM
)
(the “Company”)
,
today publishes its cash position a
s of
June 30, 2023
,
and its financial calendar for the second half of 2023
.


Cash position a


s of


June 30, 2023

As of June 30, 2023, PHAXIAM Therapeutics had cash and cash equivalents totaling €25.2 million (approximately $27.5 million).


New financial publication dates for the second half of 2023

  • Update on business and key financial data for 2


    nd


    quarter and 1


    st


    half 2023: September 21, 2023 (after US market close), followed by a conference call and webcast on September 25, 2023 (2:30 pm CET/8:30 am ET).

  • Update on business and key financial data for Q3 2023: November 14, 2023 (after US market close), followed by a conference call and webcast on November 15, 2023 (2:30 pm CET/8:30 am ET).


Upcoming investor conferences

To meet the Company’s management at one of the conferences below, please contact the organizer or PHAXIAM Therapeutics directly ([email protected]).

H.C. Wainwright BioConnect

Event link

  • Dates: Monday, September 11 – Thursday September 14, 2023
  • Place: New York
  • Participants: Thibaut du Fayet (CEO), Eric Soyer (COO & CFO), Pascal Birman (CMO)

Portzamparc BPN Paribas Biotech
&
Health Seminar

  • Dates: Wednesday, October 4 – Thursday, October 5, 2023
  • Digital format with a presentation on Tuesday October 5 from 2:30 to 3:15 pm
  • Participants: Thibaut du Fayet, Eric Soyer

Investor Access Event

Event link

  • Dates: Monday, October 9 – Tuesday, October 10, 2023
  • Place: Paris
  • Participants: Thibaut du Fayet, Eric Soyer

About PHAXIAM
Therapeutics

PHAXIAM
is
a
biopharmaceutical
company
developing
innovative
treatments
for
resistant
bacterial
infections,
which are responsible for many serious infections. The company is building on an innovative approach based on the
use of
phages,
natural
bacterial-killing
viruses.
PHAXIAM
is
developing
a
portfolio
of
phages
targeting
3
of
the
most resistant
and
dangerous
bacteria,
which
together
account
for
more
than
two-thirds
of
resistant
hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas
aeruginosa.

PHAXIAM
is
listed
on
the
Nasdaq
Capital
Market
in
the
United
States
(ticker:
PHXM)
and
on
the
Euronext
regulated market
in
Paris
(ISIN
code:
FR0011471135,
ticker:
PHXM).
PHAXIAM
is
part
of
the
CAC
Healthcare,
CAC
Pharma

& Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech
indexes. For more information, please visit


www.erytech.com

Contacts

PHAXIAM

Eric Soyer

COO & CFO
+33 4 78 74 44 38
[email protected]		 NewCap

Mathilde Bohin / Louis-Victor
Delouvrier

Investor Relations
ArthurRouillé
Media Relations
+33 1 44 71 94 94
[email protected]

Attachment